| 查看: 535 | 回复: 0 | ||
[求助]
跪求这篇英文摘要的中文啊！！感激不尽！！
|
|
Eur J Cancer. 2018 Aug 7;101:244-250. doi: 10.1016/j.ejca.2018.06.035. [Epub ahead of print] A pooled analysis of published, basket trials in cancer medicine. Hazim A1, Prasad V2. Author information Abstract BACKGROUND: There is widespread interest in cancer basket trials. However, to date, there has been no formal analysis of all published basket trials. METHODS: We performed a systematic review to identify all published basket trials in cancer medicine. We included studies that (1) did not place restriction on tumour type and (2) used a biomarker for the basis of enrolment (3) administered at least one anti-cancer agent in prospective fashion and (4) reported responses by each tumour type included. We sought information regarding the tumour histology included and the response rate in basket trials. In addition, we used national cancer statistics to identify which tumour types have been overrepresented in basket studies (i.e. more representation in trials than their incidence would suggest) and those which are under-represented. RESULTS: We identified eight articles with a combined enrolment of 1176 patients were included in our analysis, representing over 33 tumour types. Ovarian and fallopian tube cancers 221/1176 (19%), colorectal cancer 144/1176 (12%) and sarcoma 129 (11%) were the most common tumours represented, whereas renal cell cancer, seminoma, thymic carcinoma and neuroendocrine tumour and appendiceal carcinoma were the least represented with one case each. The overall response rate was 25%. Common cancers may be underrepresented compared with rarer tumour types (linear regression beta = 0.58, 95% confidence interval = -0.037-1.21) (slope < 1 implies under-representation, >1 over-representation). CONCLUSIONS: We found that, to date, over 1100 patients have been enrolled on published basket studies. Common cancers may be underrepresented compared with rarer tumours. The overall response rate was 25%. Patients enrolling on basket trials should be counselled appropriately that although these studies are highly promising, most patients did not respond. Future targets and drugs may improve on these results. Copyright ? 2018. Published by Elsevier Ltd. KEYWORDS: Basket trials; Genome driven oncology; Master protocols; Precision oncology; Tumor agnostic PMID: 30096705 DOI: 10.1016/j.ejca.2018.06.035 发自小木虫IOS客户端 |
回复此楼» 猜你喜欢
真的好想读博！
已经有17人回复
-
基金开始函评了吗？
已经有7人回复
-
博士论文被抄袭
已经有37人回复
-
求博导
已经有8人回复
-
南京大学-广州大学联合招聘博士后 欢迎广大优秀人才！！！
已经有12人回复
-
with editor 两个月了，什么原因？
已经有6人回复
-
Nature一直在编辑手里，考虑好几天了，是悬了吗
已经有9人回复
-
耗材发问
已经有4人回复
-
颜宁:基础研究应顶天立地,立地即从需求端作为问题的出发点,立项背景就是面向真实需求
已经有12人回复
-
国社科项目，你们学校都限额申报吗？
已经有9人回复
66